webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

MAL-Tri-EG-Osu

  CAS No.: 2055353-77-8   Cat No.: BADC-00628 4.5  

MAL-Tri-EG-Osu is a maleimide-based ADC linker featuring triethylene glycol units. It provides selective thiol conjugation, enabling stable and site-specific antibody-drug conjugate formation with improved pharmacokinetics and payload stability.

MAL-Tri-EG-Osu

Structure of 2055353-77-8

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Linker
Molecular Formula
C20H27N3O10
Molecular Weight
469.44
Shipping
Room temperature, or blue ice upon request.
Shipping
Please store the product under the recommended conditions in the Certificate of Analysis.

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
Mal-propionylamido-PEG3-NHS ester; (2,5-dioxopyrrolidin-1-yl) 3-[2-[2-[2-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]ethoxy]ethoxy]ethoxy]propanoate
IUPAC Name
(2,5-dioxopyrrolidin-1-yl) 3-[2-[2-[2-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]ethoxy]ethoxy]ethoxy]propanoate
Canonical SMILES
C1CC(=O)N(C1=O)OC(=O)CCOCCOCCOCCNC(=O)CCN2C(=O)C=CC2=O
InChI
InChI=1S/C20H27N3O10/c24-15(5-8-22-16(25)1-2-17(22)26)21-7-10-31-12-14-32-13-11-30-9-6-20(29)33-23-18(27)3-4-19(23)28/h1-2H,3-14H2,(H,21,24)
InChIKey
LQAQWVUOOSWWST-UHFFFAOYSA-N
Shipping
Room temperature, or blue ice upon request.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.

MAL-Tri-EG-Osu is a highly functionalized compound commonly utilized in bioconjugation applications, particularly in the development of targeted drug delivery systems such as antibody-drug conjugates (ADCs). The maleimide (MAL) group allows for efficient conjugation to thiol-containing biomolecules like antibodies, peptides, and proteins, forming stable covalent bonds. The Osu (N-hydroxysuccinimide ester) group is reactive towards primary amines, enabling the attachment of drugs, imaging agents, or other therapeutic molecules. This compound is particularly useful for site-specific conjugation, where the triethylene glycol (Tri-EG) linker provides solubility and flexibility, improving the pharmacokinetics and stability of the conjugate in vivo.

One of the most notable applications of MAL-Tri-EG-Osu is in the creation of antibody-drug conjugates (ADCs) for cancer therapy. The compound enables the efficient attachment of cytotoxic drugs to monoclonal antibodies, which can target cancer cells with high specificity. The maleimide group reacts with the thiol groups on antibodies, while the Osu group reacts with amines on the drug molecule. The triethylene glycol linker ensures that the drug is delivered precisely to the tumor site, minimizing systemic toxicity and off-target effects. The stability and solubility imparted by the Tri-EG spacer further improve the pharmacokinetics of ADCs, resulting in longer circulation times and enhanced therapeutic outcomes.

MAL-Tri-EG-Osu is also employed in peptide-drug conjugate (PDC) design, a promising strategy for targeted drug delivery. In this context, the compound facilitates the conjugation of therapeutic agents or imaging probes to peptides, which are designed to bind selectively to disease biomarkers. By attaching drugs or imaging agents to peptides, PDCs enable more precise delivery to the disease site, such as cancer or inflammation, while minimizing damage to healthy tissues. The triethylene glycol linker improves the solubility of the conjugates, enhancing their bioavailability and reducing the risk of aggregation, which can reduce therapeutic efficacy.

Additionally, MAL-Tri-EG-Osu is used in molecular imaging applications. The compound is ideal for conjugating imaging agents, such as fluorescent dyes or radiolabeled compounds, to antibodies or peptides. These conjugates can then be used for precise visualization of disease biomarkers in vivo, enabling the early detection of tumors, monitoring of treatment progress, or diagnosis of inflammatory conditions. The efficient conjugation provided by the Osu ester group and the solubility enhancement from the Tri-EG linker ensures that the imaging agents perform optimally, offering high-resolution and sensitivity for in vivo imaging studies.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Linker Development Enzyme Cleavable Linker Cathepsin B Cleavable Linker/Peptide Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker Sulfatase Cleavable Linker Chemically Cleavable Linker Non-Cleavable Linker Services Acid Cleavable Linker/Hydrazone Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Linkers - A Crucial Factor in Antibody–Drug Conjugates In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress New Structural Insights Solve Instability Issues of Maleimide Linkers in ADCs PEG Linkers in Antibody-Drug Conjugates Peptide Linkers in Antibody-Drug Conjugates Disulfide Linkers in Antibody-Drug Conjugates Biotinylation Reagents in Antibody-Drug Conjugates Maleimide Linkers in Antibody-Drug Conjugates Current ADC Linker Chemistry SPDB Linkers in Antibody-Drug Conjugates

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: 4-((S)-2-((S)-2-amino-3-methylbutanamido)-5-ureidopentanamido)benzyl 2-(pyridin-2-yldisulfanyl)ethylcarbamate | Ald-Ph-amido-PEG1-C2-Pfp ester | DNP-PEG4-NHS ester | Fmoc-L-Lys(Pentynoyl-DIM)-OH | 4-pentynoic acid succinimidyl ester | Bis(NHS)PEG9 | Sulfo-SIAB sodium | Sulfo-SIAB | NHS-PEG(5)-CO-OBzl | N-Methyl-N-[(3-methyldithio)-1-oxopropyl]-L-alanine | MAL-Tri-EG-Osu
Send Inquiry
Verification code
Inquiry Basket